LCD-DL39314
Document details
Summary
The proposed LCD addresses the billing implications for off-label uses of IVIG, which may affect reimbursement rates and eligibility for coverage under Medicare. Providers need to stay informed aboutImpact of off-label IVIG use on Medicare billing.
Affected specialty
Allergy/Immunology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=40181&ver=8CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy LCD-DL40050 · Allergy/Immunology
The proposed Local Coverage Determination (LCD) on Allergen Immunotherapy may impact billing practices for providers offering subcutaneous immunotherapy. It could lead to higher reimbursement rates fo
View alertPolicy LCD-DL40052 · Allergy/Immunology
The proposed LCD for Allergen Immunotherapy may significantly influence billing practices related to Subcutaneous Immunotherapy. Providers will need to ensure proper documentation and coding align wit
View alertPolicy LCD-DL40048 · Allergy/Immunology
The proposed LCD for Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) could have significant billing implications, particularly for allergists and practices specializing in immunoth
View alertPolicy LCD-DL36408 · Allergy/Immunology
The proposed Local Coverage Determination (LCD) for Allergen Immunotherapy with Subcutaneous Immunotherapy requires billing team review, particularly in allergy-focused practices
View alert